Intellia Therapeutics Files 8-K on Leadership Change & Q2 Update

Rhea-AI Filing Summary

Intellia Therapeutics (NTLA) filed an 8-K current report dated 7 Aug 2025 covering two disclosure items.

• Item 2.02 – Results of Operations: The company furnished a press release (Ex. 99.1) announcing Q2 2025 financial results and business updates for the period ended 30 Jun 2025. Specific revenue, EPS or guidance figures are not included in the filing; the information is furnished, not filed, and may be incorporated into future SEC filings only if explicitly referenced.
• Item 5.02 – Executive Change: Executive Vice President & Chief Medical Officer Dr. David Lebwohl, M.D. will retire effective 7 Aug 2026. He will remain CMO until a successor is appointed and stay employed through the retirement date. Upon departure, his equity awards will follow the terms of the company’s Amended & Restated Retirement Policy (filed as Ex. 10.30 to the 2022 10-K).

No other material events, financial tables, or strategic transactions are disclosed in this report.

Positive

• One-year transition window for the CMO’s retirement indicates proactive succession planning and continuity of clinical leadership.

Negative

• Upcoming departure of the Chief Medical Officer introduces future leadership risk in a science-driven organization.

Insights

Corporate Governance Expert

TL;DR Orderly one-year CMO retirement notice limits disruption; absence of financial metrics keeps overall impact neutral.

The 8-K is largely administrative. Furnishing—not filing—the Q2 press release shields the company from Section 18 liability, a standard practice. Because the actual operating metrics are omitted here, investors must consult Exhibit 99.1 to gauge financial performance. The notable governance item is Dr. Lebwohl’s planned retirement in August 2026. Providing a full-year transition period and referencing the pre-existing Retirement Policy suggest adequate succession planning, which mitigates key-person risk. However, any leadership change in clinical development for a CRISPR biotech warrants monitoring, as regulatory interactions and trial execution depend heavily on CMO leadership. With no immediate operational change and no financial data, the filing’s net investor impact is neutral.

0001652130false00016521302025-08-072025-08-07

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 07, 2025

INTELLIA THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-37766	36-4785571
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
40 Erie Street, Suite 130
Cambridge, Massachusetts				02139
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 857 285-6200

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		NTLA		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 7, 2025, Intellia Therapeutics, Inc. announced its financial results and business updates for the quarter ended June 30, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 on this Current Report on Form 8-K.

The information in this report furnished pursuant to Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Item 2.02 of this report.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 7, 2025, the Company announced that Dr. David Lebwohl, M.D., the Company’s Executive Vice President and Chief Medical Officer (“CMO”), will retire from the Company, effective August 7, 2026. Upon his retirement, Dr. Lebwohl will be eligible for the equity treatment set forth in the Company’s Amended and Restated Retirement Policy for Equity Awards (the “Retirement Policy”), a copy of which was filed as Exhibit 10.30 to the Company’s Annual Report on Form 10-K (File No. 001-37766) filed with the Securities and Exchange Commission on February 23, 2023. Dr. Lebwohl will continue to serve as the Company’s Executive Vice President and CMO until a successor is appointed and will continue to be employed by the Company until his retirement.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press release dated August 7, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			Intellia Therapeutics, Inc.
Date:	August 7, 2025	By:	/s/ John M. Leonard
			Name: John M. Leonard Title: Chief Executive Officer and President

FAQ

Why did Intellia Therapeutics (NTLA) file this 8-K?

To furnish its Q2 2025 results press release and disclose the planned retirement of Chief Medical Officer Dr. David Lebwohl.

When will Intellia’s Chief Medical Officer retire?

7 August 2026, with Dr. Lebwohl remaining in his role until a successor is appointed.

Does the 8-K include Intellia’s Q2 2025 financial figures?

No. The filing only references Exhibit 99.1 where the detailed results are provided; figures are not in the 8-K body.

What equity treatment will the retiring CMO receive?

His awards will follow Intellia’s Amended & Restated Retirement Policy for Equity Awards (Ex. 10.30, 2022 10-K).

Is the information in Item 2.02 considered "filed" with the SEC?

No. It is furnished, not filed, and is not subject to Section 18 liability unless later incorporated by reference.